[Behavior of phosphatases and carcino-embryonal antigens in serum following specific immunotherapy of metastasizing prostatic cancers].
The efficacy of specific immunotherapy was examined in patients suffering from metastatic prostatic cancer. For this purpose determination of prostatic acid phosphatase and carcino-embryonic antigen in serum was performed using conventional enzymatic and radioimmunological techniques before and after therapy. The results were as following: 1. A significant decrease of the above mentioned parameters was demonstrable after therapy. 2. The determination of prostatic acid phosphatase was helpful for immediate control of therapy, the determination of carcino-embryonic antigen was more helpful in follow-up studies. 3. Contrary to disappointing relevance of radioimmunological determined prostatic phosphatase in early prostatic cancer this parameter seemed to be more suitable in follow-up studies than conventional determined phosphatase.
D000135:Acid Phosphatase / Q000097:blood*; D001859:Bone Neoplasms / Q000556:secondary; D002272:Carcinoembryonic Antigen / Q000097:blood*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000201:enzymology / Q000276:immunology / Q000628:therapy*; D011877:Radionuclide Imaging
D002272:Carcinoembryonic Antigen; D000135:Acid Phosphatase
Das Verhalten der Phosphatasen und des karzinoembryonalen Antigens im Serum nach spezifischer Immuntherapie des entgleisten metastasierenden Prostatakarzinoms.